Immuron Limited’s Travelan Sales Surge Globally
Company Announcements

Immuron Limited’s Travelan Sales Surge Globally

Immuron Limited (AU:IMC) has released an update.

Immuron Limited reports robust sales growth for its gastrointestinal supplement Travelan, with a 13% increase globally in the September 2024 quarter, led by a significant 48% rise in North America and steady growth in Australia. The company continues to expand its market presence, securing additional pharmacy group partnerships in Australia and increasing distribution channels across North America and Canada.

For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Director’s Option Expiry Update
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Issues New Unquoted Performance Rights
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Schedules 2024 Annual General Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App